52 results on '"Preskorn SH"'
Search Results
2. CNS drug development: part I: the early period of CNS drugs.
3. Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.
4. How sequential studies inform drug development: evaluating the effect of food intake on optimal bioavailability of ziprasidone.
5. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
6. Patients who do not respond to the 'usual' dose: why Terry fell off the dose-response curve.
7. How and why study designs affect the nature and validity of study results: appearance versus true knowledge. Part II.
8. How and why study designs affect the nature and validity of study results: appearance versus true knowledge. Part I.
9. Treatment options for the patient who does not respond well to initial antidepressant therapy.
10. Neuroscience basis of clinical depression: implications for future antidepressant drug development.
11. Results of the STAR*D study: implications for clinicians and drug developers.
12. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
13. Practical application of therapeutic drug monitoring: a tale of two patients.
14. Flat dose-response curves for efficacy: what do they mean to the clinician?
15. Deconstructing a medication regimen.
16. Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
17. Clinical relevance of relative receptor binding affinity: quetiapine and ziprasidone as examples.
18. Psychopharmacology. Neuroleptic malignant syndrome resulting from a complex drug-drug interaction: 'I don't see 'em!'.
19. Psychopharmacology. The evolution of antipsychotic drug therapy: reserpine, chlorpromazine, and haloperidol.
20. Mania in a case of polypsychopharmacology: pharmacodynamic and pharmacokinetic considerations. Do you believe in magic?
21. A precautionary tale in psychiatry.
22. Polypharmacy: when is it rational?
23. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
24. Drugs are an acquired source of biological variance among patients.
25. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.
26. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I.
27. Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine.
28. Patient with bipolar disorder and familial QT prolongation: what to do?
29. Psychopharmacology and psychotherapy: what's the connection?
30. Drug-drug interactions: Proof of relevance (Part II): cause of tolerability problems or noncompliance.
31. Comments on the role of therapeutic drug monitoring for clozapine.
32. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring.
33. Clinical application of the concept of relative potency: an example involving chlorpromazine and haloperidol.
34. The difference between the formal and the functional dose: the case of the patient on thioridazine and fluvoxamine.
35. Drug-drug interactions: proof of relevance (part I).
36. Multiple medication use in patients seen in the veterans affairs healthcare system: so what?
37. Complexity of medication use in the Veterans Affairs healthcare system: Part II. Antidepressant use among younger and older outpatients.
38. Complexity of medication use in the Veterans Affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers.
39. Duloxetine.
40. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia.
41. Tianeptine: a facilitator of the reuptake of serotonin and norepinephrine as an antidepressant?
42. The recommended dosage range: how is it established and why would it ever be exceeded?
43. Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions (part II).
44. Relating clinical trials to psychiatric practice: part II: the gap between the usual patient in registration trials and in practice.
45. Classification of neuropsychiatric medications by principal mechanism of action: a meaningful way to anticipate pharmacodynamically mediated drug interactions.
46. Polypharmacy in a case of refractory major depression: part II: implications for clinical management.
47. Polypharmacy in a patient with refractory major depression: part I: the case.
48. Fatal drug-drug interaction as a differential consideration in apparent suicides.
49. Drug approvals and withdrawals over the last 60 years.
50. Multiple medications, multiple considerations.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.